| Document |
Document Title |
|
WO/2016/164413A1 |
The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or inc...
|
|
WO/2015/071657A9 |
Described herein are certain steroid derivative compounds, for example of formula (I): wherein X1, X2, X3 L, and Ar are as defined herein, pharmaceutical compositions comprising such compounds, the use of such compounds and compositions ...
|
|
WO/2016/134301A2 |
Described herein are neuroactive steroids of the Formula (I): (I) or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra, G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behav...
|
|
WO/2016/127876A1 |
The present invention relates to the field of pharmaceutical chemistry, and particularly to a crystal form of Abiraterone propionate and a preparation method therefor. Characteristic diffraction peaks occur at positions, where the 2θ va...
|
|
WO/2016/119742A1 |
The present invention relates to crystalline forms of (3β)-17-(1H-benzimidazole-1-yl)androstane-5, and 16-diene-3-ol phosphate, tartrate, and citrate and preparation methods therefor. Crystalline forms of phosphate, tartrate, and citrat...
|
|
WO/2016/111216A1 |
In this organic electroluminescent device, which has a luminescent layer containing π-conjugated molecules, when the application of a current is stopped after the current is applied, light is emitted while the current is being applied a...
|
|
WO/2016/102775A1 |
The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or ...
|
|
WO/2016/102776A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prev...
|
|
WO/2016/090139A1 |
Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined applicati...
|
|
WO/2016/082789A1 |
Described herein are neuroactive steroids of the Formula (II) : or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and ----- are as defined herein. Such compounds are envisioned, in certain...
|
|
WO/2016/086115A1 |
The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
|
|
WO/2016/082792A1 |
The present invention relates to a compound represented by general formula (I) and a stereoisomer or a pharmaceutically acceptable salt, and applications in the preparation of drugs used to prevent and treat cancers. The structure of the...
|
|
WO/2016/057931A1 |
The present invention provides a process of producing a trifluoromethoxylated aryl or trifluoromethoxylated heteroaryl having the structure: (I), wherein A is an aryl or heteroaryl, each with or without subsutitution; and R1 is -H, -(alk...
|
|
WO/2016/054472A1 |
Described herein are methods and compositions for the treatment of pancreatic cancer in a subject in need thereof. The pancreatic cancer may be resistant to other therapeutic regimens. The methods may comprise administering ARDA compound...
|
|
WO/2016/050116A1 |
Disclosed are an abiraterone derivative, namely abiraterone monosuccinate, and a preparation method therefor. The abiraterone monosuccinate is as represented by formula (I). The preparation method therefor is: carrying out an esterificat...
|
|
WO/2016/044701A1 |
Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
|
|
WO/2016/037956A1 |
The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or...
|
|
WO/2016/040322A1 |
Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor;...
|
|
WO/2014/169832A9 |
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related condi...
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2016/004910A1 |
The solution relates to a method of preparing abiraterone acetate of formula I, which comprises: a) preparation of abiraterone of formula II by the Suzuki reaction of 3-pyridyldiethylborane and a halo steroid of formula VI or VII in the ...
|
|
WO/2015/197872A1 |
The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, the use of same in the treatment of cancer, the pharmaceutical compositions containing same a...
|
|
WO/2015/188791A1 |
Disclosed is a method for preparing a Zytiga intermediate. The intermediate is trifluoromethanesulfonate of dehydroepiandrosterone acetate and has a chemical structure represented by formula (II). In the method, dehydroepiandrosterone ac...
|
|
WO/2015/177469A1 |
The present invention relates to chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, the invention enables improvement of muscular quality in sarcopenic mammals ...
|
|
WO/2015/161590A1 |
Disclosed is a method for preparing abiraterone acetate. The steps are as follows: dehydroepiandrosterone acetate and trifluoromethanesulphonic anhydride undergo a sulfonylation reaction under the catalysis of an organic base to obtain a...
|
|
WO/2015/087340A1 |
The present invention discloses a novel bile acid derivatives having substituted nitrogen functionality at C-11 and process for synthesis thereof. These C-11 substituted bile acid derivatives shows anticancer and antimycobacterial activity.
|
|
WO/2015/086596A1 |
Combinations of (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic ...
|
|
WO/2015/081170A2 |
The present invention is directed to Ganaxolone prodrugs with increased aqueous solubility and oral bioavailability relative to Ganaxolone and that enable development of stable extended release formulations which offer a significant ther...
|
|
WO/2015/023710A1 |
Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods...
|
|
WO/2015/014686A1 |
The present invention relates to a novel process for the synthesis of abiraterone and in particular abiraterone acetate, a compound of formula (I) reported below: having pharmacological activity suitable for slowing down the progression ...
|
|
WO/2015/015246A1 |
The present invention relates to a novel process for the synthesis of abiraterone, and in particular of abiraterone acetate, compound of formula (I) reported below: N O (I) which has pharmacological activity useful tor slowing down the p...
|
|
WO/2015/000451A1 |
The invention relates to a new solid form of abiraterone acetate of formula I, in particular the benzenesulfonic, p-toluenesulfonic and fumaric acid salts, in a crystalline or amorphous form. The invention also provides a process for the...
|
|
WO/2014/207762A1 |
The present invention relates to improvement in the process of preparation of abiraterone acetate or a pharmaceutically acceptable salt thereof wherein the improvement comprises purifying the crude 3-&-acetoxyandrosta-5,16-diene-17-yl tr...
|
|
WO/2014/207311A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in trea...
|
|
WO/2014/207309A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or preve...
|
|
WO/2014/207310A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2to R7are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevent...
|
|
WO/2014/197653A2 |
Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
|
|
WO/2014/169831A1 |
Provided herein are19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, ⃜⃜, R1, R2, R3a, R3b, R4a, and R 4bare as defined herein, and A is a carbon bound substituted or unsubstitu...
|
|
WO/2014/170221A1 |
The present invention relates to a process for the preparation of 17-substituted steroids and, more particularly, to an improved method of preparing micro size abiraterone or derivatives thereof in high yield and purity by means of a sph...
|
|
WO/2014/169836A1 |
Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditi...
|
|
WO/2014/160441A1 |
Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an altera...
|
|
WO/2014/128108A1 |
The invention relates to AKR1C3 inhibitors of the formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment an...
|
|
WO/2014/108452A1 |
A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, ...
|
|
WO/2014/102833A2 |
The present invention provides a novel process for the preparation of abiraterone. The present invention also provides a novel process for the preparation of abiraterone acetate.
|
|
WO/2014/091158A1 |
The present invention relates to testosterone derivatives of formula (I): in which n is an integer between 1 and 10 and Y is an activated or ready-to-be-activated group which enables the formation of an amide bond with a primary amine of...
|
|
WO/2014/083512A1 |
The present invention relates to process for the preparation of abiraterone acetate, its salts and intermediates thereof, crystalline forms of abiraterone acetate salts and purification of abiraterone acetate.
|
|
WO/2014/075978A1 |
The present invention relates to a process for making abiraterone-3-acetate of formula (1) starting from dehydroepiandrosterone-3-acetate of formula (2) by converting it into the triflate of formula (5) in an inert solvent in the presenc...
|
|
WO/2014/071984A1 |
The present invention relates to an improved process for making abiraterone-3-acetate of formula (1) starting from dehydroepiandrosterone-3-acetate (DHEA) of formula (2). In particular, it relates to an improved process of converting the...
|
|
WO/2014/071983A1 |
The present invention relates to a process for making the compound 3β-acetoxy- androsta-5,16-dien-17-yl trifluoromethanesulfonate of formula (5) and is characterized in that dehydroepiandrosterone-3-acetate of formula (2) is reacted wit...
|
|
WO/2014/064032A1 |
The invention relates to a process for the purification of crude abiraterone acetate by treatment with polymer resins in aqueous solvent. The purified product is recovered by simple concentration and filtration.
|
